Ironwood Pharmaceuticals Inc. on Monday said that its new drug for irritable bowel syndrome with constipation is now available in the United States, marketed as Linzess (the trade name for linaclotide). It is estimated that irritable bowel syndrome afflicts 30 million to 40 million Americans. The stock rose Monday, fell Tuesday and Wednesday, then gained 3.2 percent Thursday. On Tuesday, Zacks upgraded the shares to “outperform,” with a $12 target price, Jagsreport.com said.
Ironwood stock posts a 3.3 percent gain
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week